Get started
Author

Sylwia Piasecka

ORCID: 0000-0002-8485-2838
Observed ORCID: 0000-0002-8485-2838
OpenAlex ID: A5040948626
Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2023 · Bartlomiej Borek, Julita Nowicka, et al. · Molecular Cancer Therapeutics · 43
PDF
Phosphoramidate Ligation of Oligonucleotides in Nanoscale Structures
2016 · Matthäus Kalinowski, Rüdiger Haug, et al. · ChemBioChem · 40
Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis
2020 · Robert Koralewski, Barbara Dymek, et al. · Journal of Medicinal Chemistry · 32
Building expanded structures from tetrahedral DNA branching elements, RNA and TMV protein
2018 · Nana L. Wenz, Sylwia Piasecka, et al. · Nanoscale · 11
Supplementary Figure 22 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2023 · Bartlomiej Borek, Julita Nowicka, et al. · 2
Supplementary Figure 21 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Tables 1-11 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 1 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 15 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 17 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 16 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Materials and Methods from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 23 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 19 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 18 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 20 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figures 2 - 14 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 22 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 16 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 1 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 23 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figures 2 - 14 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Materials and Methods from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 21 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Supplementary Figure 17 from Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
2024 · Bartlomiej Borek, Julita Nowicka, et al.
Works count: 64
Citation count: 128
H-index: 4
I10-index: 4
Year
Topic
Type